Insight Molecular Diagnostics Inc. Files 8-K on Officer/Director Changes
Ticker: IMDX · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1642380
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Insight Molecular Diagnostics Inc. (ICDX) filed an 8-K detailing changes in its board and executive team as of Sept 28, 2025.
AI Summary
Insight Molecular Diagnostics Inc. filed an 8-K on October 2, 2025, reporting events as of September 28, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership and officer appointments can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Insight Molecular Diagnostics Inc. (company) — Registrant
- September 28, 2025 (date) — Date of earliest event reported
- October 2, 2025 (date) — Filing date
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any details on new compensatory arrangements?
Yes, the filing covers compensatory arrangements of certain officers.
What is the primary business of Insight Molecular Diagnostics Inc.?
Insight Molecular Diagnostics Inc. is involved in IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES, with SIC code 2835.
When was the company incorporated and where is its principal office?
The company is incorporated in California and its business address is 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN 37217.
Has the company undergone name changes previously?
Yes, the company was formerly known as Oncocyte Corp, with name changes recorded on September 20, 2021, February 13, 2020, and February 5, 2020.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2025-10-02 16:05:30
Key Financial Figures
- $3 — e. The exercise price of the options is $3.33, the closing price of the Company's
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex10-1.htm (EX-10.1) — 15KB
- 0001493152-25-016685.txt ( ) — 220KB
- imdx-20250928.xsd (EX-101.SCH) — 3KB
- imdx-20250928_lab.xml (EX-101.LAB) — 33KB
- imdx-20250928_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INSIGHT MOLECULAR DIAGNOSTICS INC. Date: October 2, 2025 By: /s/ Peter Hong Peter Hong Vice President, General Counsel